Having an exam reflects multiple factors. 1 key finding →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
When considering race/ethnicity, the presence of more vascular comorbidities drove greater vulnerability. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among the included 3 515 329 Medicare fee-for-service decedents, when adjusted for age and sex, the percentage of older decedents with an ADRD diagnosis increased from 34.7% in 2004 to 47.2% in 2017. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
52/100
In total, 1006 elderly were interviewed, with a 66.18% response rate. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
The age-adjusted prevalence rates of dementia (2.29%) and Alzheimer's disease (1.41%) in the Ibadan sample were significantly lower than those in the Indianapolis sample, both in the community-dwelling subjects alone (4.82% and 3.69%, respectively) and in the combined nursing home and community samples (8.24% and 6.24%, respectively). 2 key findings →
Participants: 2,494 Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia is often unrecognized and undocumented in private practice settings. 1 key finding →
Design: cross-sectional Participants: 18 Evidence: low
Full summary, score breakdown and related studies → Original source
Recent Medicare claims perform reasonably well in identifying dementia; however, there are consistent differences in cases of dementia identified through claims than in rigorous cohort evaluations. 5 key findings →
Participants: 54 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Algorithms developed from health administrative data are sensitive and specific for identifying older adults with AD-RD. 1 key finding →
Participants: 3,404 Evidence: low
Full summary, score breakdown and related studies → Original source
In this study, mental disorders were associated with the onset of dementia in the population. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Total cost of care in early stage AD (CDR-SB ≤ 4) was 16,448€ (95% CI 13,722-19,716) annually. 5 key findings →
Participants: 231 Evidence: low
Full summary, score breakdown and related studies → Original source
Black older adults are less likely to move to assisted living and are more likely to move to a nursing home compared to white older adults. 3 key findings →
Participants: 5,212 Evidence: low
Full summary, score breakdown and related studies → Original source
Compared with Non-Hispanic White (NHW) adults, Non-White adults had a higher incidence of AD-specific (hazard ratio [HR] = 2.05, 95% confidence interval [CI]: 1.21, 3.49) and all-cause dementia (HR = 2.01, 95% CI: 1.36, 2.98). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of low vision in the Medicare population was 994/100,000 and increased significantly with age, Black (1,854/100,000) or Hispanic (2,862/100,000) race/ethnicity, female gender (1,181/100,000), and Medicaid eligibility (2,975/100,000). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Just under a half of the expected numbers of patients with dementia are recognised in GP dementia registers. 4 key findings →
Participants: 351 Evidence: low
Full summary, score breakdown and related studies → Original source
Although persons with dementia are frequently hospitalized, relatively little is known about the health profile, patterns of health care use, and mortality rates for patients with dementia who access care in the emergency department (ED). 4 key findings →
Participants: 10,354 Evidence: low
Full summary, score breakdown and related studies → Original source
More than half of nursing home residents suffer from dementia, which is about 19-fold higher than the prevalence in insured living in the community. 1 key finding →
Participants: 213,694 Evidence: low
Full summary, score breakdown and related studies → Original source
Asthma, allergic rhinitis, and atopic dermatitis were significantly associated with increased risk of all-cause dementia and subtypes, with dose-effect relationships with the severity of allergic diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This article describes the protocol for the Systematic Multi-domain Alzheimer's Risk Reduction Trial (SMARRT), a single-blind randomized pilot trial to test a personalized, pragmatic, multi-domain Alzheimer's disease (AD) risk reduction intervention in a US integrated healthcare delivery system. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
In a sample of 2,398,405 patients receiving primary care, the target population relevant for dementia prevention measures in 2018 consisted of 191,883 patients with hypertension, 23,308 with obesity, 5,059 with hearing loss, 120,200 with diabetes and 43,233 with depression. 5 key findings →
Participants: 51 Evidence: low
Full summary, score breakdown and related studies → Original source
Among 769 randomized dyads, 73% were spousal, 14% adult child, and 13% other dyads. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
We identified a cohort of 3619 incident dementia cases, 38.9% were male, and 66.9% were non-Hispanic White. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia. 1 key finding →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
In both databases, total healthcare resource utilization and costs increased with number of core features. 4 key findings →
Participants: 536 Evidence: low
Full summary, score breakdown and related studies → Original source
On average, ADRD diagnosis was not significantly associated with excess Medicare payments over the last 5 years of life. 5 key findings →
Participants: 4,899 Evidence: low
Full summary, score breakdown and related studies → Original source
Most PWD (67%) met criteria for another manifestation of serious illness (24% advanced medical condition, 44% ADL impairment). 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
From across this tag
9 of the 265 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Post-disclosure distress among racial and ethnic groups in a preclinical AD trial
- Poorer outcomes and greater healthcare costs for hospitalised older people with dementia and delirium: a retrospective cohort study
- Programme Dementia Prevention (pdp): A Nationwide Program for Personalized Prevention in Luxembourg
- Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana
- Predictors of falls in older adults with and without dementia
- Deaths in the United States among persons with Alzheimer's disease (2010-2050)
- Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons
- Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need
- Screening for intrinsic capacity impairments as markers of increased risk of frailty and disability in the context of integrated care for older people: Secondary analysis of MAPT
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →